Preclinical development of NaPi2b-PL2202, a novel camptothecin- based antibody-drug conjugate targeting solid tumors expressing NaPi2b

被引：0
|
作者：
Horsley, Elizabeth
Jabeen, Asma
Veillard, Nicolas
Havenith, Karin
Janghra, Narinder
Alves, Pedro
Oblette, Cecile
Kirby, Ian
Hogg, Paul W.
Zammarchi, Francesca
de Haan, Lolke
van Berkel, Patrick
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5085
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical characterization of NaPi2b-PL2202, a novel exatecan-based antibody drug conjugate
    Jabeen, A.
    Janghra, N.
    Horsley, E.
    Gallagher, C.
    Oblette, C.
    Kamenski, A.
    van Berkel, P. H.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S68 - S68
  • [2] Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
    Mosher, Rebecca
    Poling, Laura
    Qin, LiuLiang
    Bodyak, Natalya
    Bergstrom, Donald
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [3] Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6
    Tsang, Nicola
    Veillard, Nicolas
    Horsley, Elizabeth
    Havenith, Karin
    Janghra, Narinder
    Zaitseva, Kristina
    Oblette, Cecile
    Kirby, Ian
    Hogg, Paul W.
    Zammarchi, Francesca
    de Haan, Lolke
    van Berkel, Patrick H.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b
    Huang, Wentao
    Liu, Zhifang
    Li, Yifan
    Pan, Heng
    Qin, Xia
    Fei, Da
    Li, Runsheng
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
    Tolcher, Anthony W.
    Ulahannan, Susanna Varkey
    Papadopoulos, Kyriakos P.
    Edenfield, William Jeffery
    Matulonis, Ursula A.
    Burns, Timothy F.
    Mosher, Rebecca
    Fielman, Barbara
    Hailman, Eric
    Burris, Howard A.
    Moore, Kathleen N.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker- payload for treatment of solid tumors
    Xiao, Liang
    Lian, Wei
    Liu, Qigang
    Zong, Qing
    Song, Shuai
    Stann, Sasha
    Cai, Jiaqiang
    Xue, Tongtong
    CANCER RESEARCH, 2024, 84 (06)
  • [7] The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
    Bodyak, Natalya D.
    Mosher, Rebecca
    Yurkovetskiy, Aleksandr, V
    Yin, Mao
    Bu, Charlie
    Conlon, Patrick R.
    Demady, Damon R.
    DeVit, Michael J.
    Gumerov, Dmitry R.
    Gurijala, Venu R.
    Lee, Winnie
    McGillicuddy, Dennis
    Park, Peter U.
    Poling, Laura L.
    Protopova, Marina
    Qin, LiuLiang
    Stevenson, Cheri A.
    Ter-Ovanesyan, Elena
    Uttard, Alex
    Xiao, Dongmei
    Xu, Jian
    Xu, Ling
    Bergstrom, Donald A.
    Lowinger, Timothy B.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (05) : 896 - 905
  • [8] A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
    Bergstrom, Donald
    Bodyak, Natalya
    Yurkovetskiy, Alex
    Poling, Laura
    Yin, Mao
    Protopopova, Marina
    Devit, Mike
    Qin, Liuliang
    Gumerov, Dmitry
    Ter-Ovanesyan, Elena
    Mosher, Rebecca
    Lowinger, Timothy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S396 - S397
  • [9] Preclinical development of a novel antibody-drug conjugate targeting "cold" tumors
    Kaplan, Angelo
    Attanasio, Nickolas
    Do, To Uyen T.
    Swaminathan, Sudha
    Bisht, Arnima
    Lou, San Lin
    Allen, Jason
    Boyd, Robert
    Ackroyd, James E.
    Feldman, Gleb
    Rohlff, Christian
    Dusek, Rachel L.
    CANCER RESEARCH, 2018, 78 (13)
  • [10] Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers
    Lin, Kedan
    Rubinfeld, Bonnee
    Zhang, Crystal
    Firestein, Ron
    Harstad, Eric
    Roth, Leslie
    Tsai, Siao Ping
    Schutten, Melissa
    Xu, Keyang
    Hristopoulos, Maria
    Polakis, Paul
    CLINICAL CANCER RESEARCH, 2015, 21 (22) : 5139 - 5150
12345